Provokable left ventricular outflow tract obstruction in a patient without hypertrophy

Nature Reviews Cardiology

Volumn 6, Issue 4, 2009, Pages 313-316

  Pasquale, Ferdinando ^a   Tomé Esteban, Maria Teresa ^a   Morgagni, Riccardo ^b   Elliott, Perry ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; DISOPYRAMIDE; ANTIARRHYTHMIC AGENT;

ADULT; ANGIOCARDIOGRAPHY; ANTICHOLINERGIC SYNDROME; ARTICLE; ARTIFICIAL HEART PACEMAKER; BICYCLE ERGOMETRY; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DYSPNEA; EXERCISE TEST; FAMILY HISTORY; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HUMAN; LETHARGY; MALE; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; ANGINA PECTORIS; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; DRUG COMBINATION; HEART FUNCTION TEST; HEART OUTFLOW TRACT OBSTRUCTION; HEART PACING; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

ANGINA PECTORIS; ANTI-ARRHYTHMIA AGENTS; ATENOLOL; CARDIAC PACING, ARTIFICIAL; DIAGNOSTIC IMAGING; DISOPYRAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSPNEA; HEART FUNCTION TESTS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 67649641936     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.7     Document Type: Article

References (11)

1. Maron, B. J. et al. american college of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. a report of the american college of cardiology Foundation task Force on clinical expert consensus documents and the european society of cardiology committee for Practice Guidelines. J. Am. Coll. Cardiol. 42, 1687-1713 (2003).
2. Maron, M. s. et al. effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295-303 (2003).
3. shah, J. s. et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 94, 1288-1294 (2008).
4. Maron, M. s. et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114, 2232-2239 (2006).
5. Page, s. P., Pnatazis, a. & elliott, P. M. acute myocardial ischemia associated with latent left ventricular outflow tract obstruction in the absence of left ventricular hypertrophy. J. Am. Soc. Echocardiogr. 20, 772.e1-772.e4 (2007).
6. Bos, J. M. et al. Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy. Am. Heart J. 155, 1128-1134 (2008).
7. Fananapazir, L. et al. Long-term results of dualchamber (ddd) pacing in obstructive hypertrophic cardiomyopathy. evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 90, 2731-2742 (1994).
8. Nishimura, R. a. et al. dual-chamber pacing in hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J. Am. Coll. Cardiol. 29, 435-441 (1997).
9. Maron, B. J. et al. assessment of permanent dual-chamber pacing as a treatment for drugrefractory symptomatic patients with obstructive hypertrophic cardiomyopathy. a randomized, double-blind, crossover study (M-PatHy). Circulation 99, 2927-2933 (1999).
10. Linde, c., Gadler, F., Kappenberger, L. & Rydén L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIc study Group. Pacing In cardiomyopathy. Am. J. Cardiol. 83, 903-907 (1999).
11. Binder, J., Ommen, s. R., sorajja, P., Nishimura, R. a. & tajik, a. J. clinical and echocardiographic variables fail to predict response to dual-chamber pacing for hypertrophic cardiomyopathy. J. Am. Soc. Echocardiogr. 21, 796-800 (2008).